Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 5/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | CA9 | Q16790 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 3/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769572 | 1.00 | SLC7A5 (0.48) | SLC7A5TSHRDPP4FAPDPP8 | |
| SCHEMBL769573 | 1.00 | SLC7A5 (0.48) | SLC7A5TSHRDPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL1456828 | 0.97 | SLC7A5 (0.46) | SLC7A5TSHRDPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL17099133 | 0.97 | SLC7A5 (0.46) | SLC7A5TSHRDPP4FAPDPP8 | |
| SCHEMBL11789453 | 0.84 | TSHR (0.43) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| SCHEMBL28500308 | 0.84 | TSHR (0.43) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| SCHEMBL11789459 | 0.84 | TSHR (0.43) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| SCHEMBL145865 | 0.84 | SLC7A5 (0.48) | SLC7A5TSHRDPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL18075532 | 0.82 | TSHR (0.42) | SLC7A5TSHRDPP4DPP7HCAR2 | |
| Hydrochloric Acid SCHEMBL18075258 | 0.82 | TSHR (0.42) | SLC7A5TSHRDPP4DPP7HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214426-A1 | PROCESS FOR THE PREPARATION OF R-OXYBUTYNIN HYDROCHLORIDE | HARMAN FINOCHEM LIMITED (IN) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023088441-A1 | KIF18A INHIBITOR | 微境生物医药科技(上海)有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2022247770-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海璎黎药业有限公司 | 2022-12-01 | — | — | WO | disclosed |
| US-11033556-B2 | Bicyclic sulfonamides | ALIGOS THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200345749-A1 | BICYCLIC SULFONAMIDES | ALIGOS THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10696708-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10421771-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORP (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921546-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8557810-B2 | Imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2012-05-24 | — | — | US | disclosed |
| US-8129374-B2 | Method of using imidazolothiazole compounds for the treatment of disease | AMBIT BIOSCIENCE CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7820657-B2 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126505-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | SLC7A5 4173/4885TSHR 415/4885DPP4 1781/4885 |
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | SLC7A5 1251/4885TSHR 3355/4885DPP4 278/4885 |
| US-20140243525-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | SLC7A5 4173/4885TSHR 415/4885DPP4 1781/4885 |
| US-20120129850-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK3 | SLC7A5 4173/4885TSHR 415/4885DPP4 1781/4885 |
| US-20100298313-A1 | METHOD OF USING IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | GRK2, GRK4, GRK5 | SLC7A5 4688/4885TSHR 566/4885DPP4 1679/4885 |
| US-10696708-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, NT5C2 | SLC7A5 1502/4885TSHR 3730/4885DPP4 253/4885 |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | SLC7A5 323/4885TSHR 1218/4885DPP4 1542/4885 |
| US-11033556-B2 | Bicyclic sulfonamides | STS, SULT2A1, ARSA | SLC7A5 352/4885TSHR 1724/4885DPP4 1491/4885 |
| US-20200345749-A1 | BICYCLIC SULFONAMIDES | STS, SULT2A1, ARSA | SLC7A5 352/4885TSHR 1724/4885DPP4 1491/4885 |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | SLC7A5 844/4885TSHR 3939/4885DPP4 491/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | SLC7A5 4768/4885TSHR 395/4885DPP4 1364/4885 |
| US-10421771-B2 | — | PNP, ADAR, NT5C2 | SLC7A5 2425/4885TSHR 3846/4885DPP4 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.